This post was originally published on this site
Shares in the drugmaker rose 4.5% on the announcement.
This additional revenue comes in addition to the previously announced forecast of $8B to $15B in expected sales from the respiratory franchise in 2027.
Moderna also expects COVID-19 vaccine sales to range from $6B to $8B in 2023, with the specific figures dependent on US vaccination rates.
The company also said that its flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial.
“Our mRNA platform is working. With today’s positive Phase 3 flu results, along with previous results in COVID and RSV, we are now three for three on advancing respiratory disease programs to positive Phase 3 data,” said Stéphane Bancel, Chief Executive Officer of Moderna.
The products in oncology, rare, and latent diseases should provide a meaningful boost to Moderna’s top-line growth. Over the next five years, the company expects to launch up to 15 new products addressing high unmet needs.
